These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24367658)

  • 1. Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
    Ross RL; Burns JE; Taylor CF; Mellor P; Anderson DH; Knowles MA
    PLoS One; 2013; 8(12):e84411. PubMed ID: 24367658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
    Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
    Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p85alpha subunit of phosphatidylinositol 3'-kinase binds to and stimulates the GTPase activity of Rab proteins.
    Chamberlain MD; Berry TR; Pastor MC; Anderson DH
    J Biol Chem; 2004 Nov; 279(47):48607-14. PubMed ID: 15377662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived mutations within the N-terminal domains of p85α impact PTEN or Rab5 binding and regulation.
    Mellor P; Marshall JDS; Ruan X; Whitecross DE; Ross RL; Knowles MA; Moore SA; Anderson DH
    Sci Rep; 2018 May; 8(1):7108. PubMed ID: 29740032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
    Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
    Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
    Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
    Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism.
    Thapa N; Chen M; Cryns VL; Anderson R
    Cell Rep; 2024 May; 43(5):114119. PubMed ID: 38630589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.
    Cheung LW; Walkiewicz KW; Besong TM; Guo H; Hawke DH; Arold ST; Mills GB
    Elife; 2015 Jul; 4():e06866. PubMed ID: 26222500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
    Hon WC; Berndt A; Williams RL
    Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of p85α Alterations in Cancer.
    Marshall JDS; Whitecross DE; Mellor P; Anderson DH
    Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30650664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
    Li X; Lau AYT; Ng ASN; Aldehaiman A; Zhou Y; Ng PKS; Arold ST; Cheung LWT
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
    Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
    Hofmann BT; Jücker M
    Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
    Ross RL; Askham JM; Knowles MA
    Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.